百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

已收盘 01-13 16:08:13

204.000

+0.600

+0.29%

最高207.400	最低199.700	成交量480.76万
今开202.400	昨收203.400	日振幅3.79%
总市值3,144亿	流通市值2,909亿	总股本15.41亿
成交额9.77亿	换手率0.34%	流通股本14.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":204,"timestamp":1768291693006,"preClose":203.4,"halted":0,"volume":4807602,"delay":0,"floatShares":1426000000,"shares":1541000000,"eps":-3.674526719760376,"marketStatus":"已收盘","change":0.6,"latestTime":"01-13 16:08:13","open":202.4,"high":207.4,"low":199.7,"amount":977458015,"amplitude":0.037856,"askPrice":204,"askSize":22400,"bidPrice":203.8,"bidSize":600,"shortable":3,"etf":0,"ttmEps":0.3508396970382446,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":203.4,"openAndCloseTimeList":[[1768267800000,1768276800000],[1768280400000,1768291200000]],"volumeRatio":0.90088,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":310.8,"timestamp":1768287600000,"preClose":313.31,"halted":0,"volume":3645300,"delay":0,"premium":"-41.32"}},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2603260503","title":"科创医药ETF华夏开盘涨0.49%，重仓股联影医疗涨1.64%，百济神州跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603260503","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603260503?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:35","pubTimestamp":1768268100,"startTime":"0","endTime":"0","summary":"1月13日，科创医药ETF华夏（588130）开盘涨0.49%，报1.221元。其重仓股表现各异，联影医疗涨1.64%，百济神州跌0.22%，百利天恒、惠泰医疗、泽璟制药、博瑞医药、华大智造等均上涨，艾力斯跌0.27%，君实生物涨0.28%，荣昌生物涨幅最大，达15.33%。该ETF业绩比较基准为上证科创板生物医药指数收益率，由华夏基金管理有限公司管理，基金经理鲁亚运，自2025年5月14日成立以来回报为20.44%，近一个月回报为7.28%。市场有风险，投资需谨慎，本文信息仅作参考，不构成个人投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113104756a713b2c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113104756a713b2c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1770034418.SGD","BK1588","LU1719994722.HKD","LU1303224171.USD","BK1583","LU1969619763.USD","06160","LU0588546209.SGD","LU2328871848.SGD","LU1251922891.USD","BK1500","BK1161","LU0307460666.USD"],"gpt_icon":0},{"id":"2603059578","title":"百济神州跌1.67% 股价跌破200港元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2603059578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603059578?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:31","pubTimestamp":1768267919,"startTime":"0","endTime":"0","summary":"2026年01月13日早盘09时31分，百济神州股票出现波动，股价急速下挫1.67%。截至发稿，该股报200.000港元/股，成交量32.4456万股，换手率0.02%，振幅1.43%。资金方面，该股资金流入1382.38万港元，流出2955.14万港元。机构评级方面，在所有12家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。百济神州股票所在的生物技术行业中，整体涨幅为0.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113093159a713820b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113093159a713820b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","06160","LU0588546209.SGD","BK1500","BK1588","LU1719994722.HKD","LU1770034418.SGD","LU2328871848.SGD","BK1161","LU1303224171.USD","BK1583","LU1251922891.USD","LU1969619763.USD"],"gpt_icon":0},{"id":"2602933518","title":"JPM 2026前瞻 | 中国创新药站上全球舞台中央","url":"https://stock-news.laohu8.com/highlight/detail?id=2602933518","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602933518?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:58","pubTimestamp":1768208280,"startTime":"0","endTime":"0","summary":"2026年第44届摩根大通医疗健康大会将于1月12日至15日在美国旧金山举行。据披露，本届JPM的议题与参会企业或将高度集中于六大核心领域，其中生物技术板块占比最高，预计接近35%。目前，已有多家国内企业确认参会，且覆盖CXO与创新药两大核心群体。从行业趋势看，本届JPM或将进一步强化两条技术主线。进入2026年，这一趋势仍在延续。宜联生物B7H3 ADC授权给罗氏此次JPM 2026将成为国内药企集中展示核心分子竞争力、推动海外BD合作的重要窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","03696","LU2328871848.SGD","09688","BK1161","09995","02359","02269","BK1583","06978","LU1969619763.USD","02615","06160","01276","01530"],"gpt_icon":0},{"id":"2602902425","title":"中国力量在JPM大会的闪耀时刻：24家国产企业双线发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2602902425","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602902425?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:36","pubTimestamp":1768206992,"startTime":"0","endTime":"0","summary":"而今年，中国力量成为舞台上最耀眼的星光之一：24家国产医药企业集体亮相，以“主会场引领、亚太专场扩容”的双线布局，向世界展示中国医药产业的创新硬实力与全球化野心。结 语从主会场的核心发声到亚太专场的集体亮相，24家中国药企在JPM大会的舞台上，用实打实的研发成果、商业化突破与海外合作，书写着中国医药的全球化篇章。这不仅是中国力量的闪耀时刻，更预示着2026年中国创新药将在全球舞台上迎来更多突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165035a710cae5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165035a710cae5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1770034418.SGD","01276","LU1251922891.USD","LU0588546209.SGD","LU1719994722.HKD","LU2328871848.SGD","BK1574","LU0307460666.USD","06978","06990","BK1500","BK1588","06160","02269","09688","LU1303224171.USD","LU1969619763.USD","LU2488822045.USD","01530","BK1583","BK1161","09995","02359"],"gpt_icon":0},{"id":"2603457803","title":"每日卖空追踪 | 百济神州 01月12日卖空量成交40.64万股，卖空比例为8.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603457803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603457803?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:30","pubTimestamp":1768206635,"startTime":"0","endTime":"0","summary":"百济神州北京时间01月12日，涨3.09%，卖空量成交40.64万股，较上一交易日减少83.46%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165134a4b9d696&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165134a4b9d696&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1969619763.USD","BK1588","LU0307460666.USD","BK1500","LU1770034418.SGD","BK1161","06160","LU1251922891.USD","LU1303224171.USD","LU2328871848.SGD","LU0588546209.SGD","LU1719994722.HKD"],"gpt_icon":0},{"id":"2602533143","title":"每周股票复盘：百济神州（688235）授出693,186股普通股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2602533143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602533143?lang=zh_cn&edition=full","pubTime":"2026-01-11 01:52","pubTimestamp":1768067531,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，百济神州报收于312.99元，较上周的268.6元上涨16.53%。本周，百济神州1月9日盘中最高价报317.84元。百济神州有限公司截至2025年12月31日，法定注册资本为231,146.38美元，已发行普通股总数为1,425,622,549股，另在上海科创板上市人民币股份115,055,260股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0588546209.SGD","LU1770034418.SGD","BK1161","BK0239","BK1588","06160","688235","LU0307460666.USD","LU1303224171.USD","BK1583","LU1969619763.USD","LU1251922891.USD","LU1719994722.HKD","BK1500","LU2328871848.SGD"],"gpt_icon":0},{"id":"2602588297","title":"每日卖空追踪 | 百济神州 01月09日卖空量成交124.85万股，卖空比例为19.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602588297","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602588297?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:30","pubTimestamp":1767947436,"startTime":"0","endTime":"0","summary":"百济神州北京时间01月09日，跌1%，卖空量成交124.85万股，较上一交易日增加74.52%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163913a4af8563&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163913a4af8563&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","LU0588546209.SGD","BK1161","LU1303224171.USD","LU2328871848.SGD","LU1719994722.HKD","BK1588","LU1969619763.USD","BK1500","LU1251922891.USD","06160","BK1583","LU1770034418.SGD"],"gpt_icon":0},{"id":"1128958057","title":"港交所推出六只新股票期权，包括紫金黄金国际、老铺黄金、地平线机器人等，1月19日开始买卖","url":"https://stock-news.laohu8.com/highlight/detail?id=1128958057","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128958057?lang=zh_cn&edition=full","pubTime":"2026-01-09 13:19","pubTimestamp":1767935995,"startTime":"0","endTime":"0","summary":" $香港交易所(00388)$ 宣布将推出六只新股票期权（仅限每月到期期权）并于2026 年 1 月 19 日（星期一）（「开始交易日」）开始买卖，包括紫金黄金国际、老铺黄金、地平线机器人等。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/8bff26889e5f42acbe22c7bd91f5be44","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/8bff26889e5f42acbe22c7bd91f5be44"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"836eccfa0ddb96db25d89773a6907fbb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"港交所推出六只新股票期权，包括紫金黄金国际、老铺黄金、地平线机器人等，1月19日开始买卖","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","02259","06181","09660","06160","09926"],"gpt_icon":0},{"id":"2602884312","title":"【券商聚焦】华泰证券：开年以来的流动性修复有望提振创新药板块β","url":"https://stock-news.laohu8.com/highlight/detail?id=2602884312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602884312?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:58","pubTimestamp":1767920334,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，自9月港股创新药年内新高以来，港股创新药指数截止到年底回调24%，而同期美股生物科技指数XBI涨幅29%，NBI指数涨幅18%。XBI自4月底部反弹超过100%，大型MNC普遍自底部反弹30~50%，礼来市值首次突破万亿美金。步入新的一年，港股创新药迎来开门红。随着流动性修复及对外BD持续，以及JPM峰会、年报周期的BD旺季和数据披露高峰的到来，该机构认为开年以来的流动性修复有望提振创新药板块β，上涨趋势有望持续。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972900","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","LU1934453819.USD","LU0307460666.USD","LU0501845795.SGD","LU1152091168.USD","LU0417516571.SGD","01093","LU0039217434.USD","BK1589","LU0561508036.HKD","01877","IE0008369823.USD","LU0516422440.USD","LU1807302812.USD","09926","LU2476274720.SGD","LU0043850808.USD","BK0012","LU2148510915.USD","02142","LU1064131003.USD","LU2097828474.EUR","LU1960683339.HKD","01801","09995","IE00B5MMRT66.SGD","LU3063872942.SGD","06978","LU1979443071.USD","02616","06160","LU1993786604.SGD","BK0183","BK1500","LU0588546209.SGD","159992","LU1242518857.USD","LU2097828805.USD","LU0067412154.USD","01177","06185","09688","LU1226287792.SGD","02269","LU1328277881.USD","LU0516422952.EUR","LU0502904849.HKD","601688","BK1141","LU0315179316.USD"],"gpt_icon":0},{"id":"2601949398","title":"创新药“华山奖”企业奖36家入围名单公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2601949398","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601949398?lang=zh_cn&edition=full","pubTime":"2026-01-08 18:19","pubTimestamp":1767867540,"startTime":"0","endTime":"0","summary":"“医学界”与“同写意”共同发起的创新药“华山奖”企业奖入围名单公布，共36家企业入围。奖项旨在发现中国创新药价值医疗标杆，通过量化指标评选产生。奖项分三类：最佳领导型创新医药企业奖，要求企业具有卓越综合实力、深远行业影响力等，年药品销售收入在100亿元以上，百济神州、阿斯利康等12家企业入围；最佳成长型创新医药企业奖，要求企业展现出卓越成长潜力，年药品销售收入处于10亿-100亿元之间，信达生物、传奇生物等12家企业入围；最佳潜力型创新医药企业奖，要求企业展现出卓越创新能力，年药品销售收入在10亿元以下或未有商业化产品，和铂医药、科伦博泰生等2家企业（名单未完全列举）入围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108184317a4abbfff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108184317a4abbfff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","06978","02142","BK1583","06160"],"gpt_icon":0},{"id":"2601356555","title":"2026开年已经有3款创新药密集获批上市，来自恒瑞、百济、赛诺菲","url":"https://stock-news.laohu8.com/highlight/detail?id=2601356555","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601356555?lang=zh_cn&edition=full","pubTime":"2026-01-08 13:44","pubTimestamp":1767851095,"startTime":"0","endTime":"0","summary":"2026新年伊始，医药行业便传来阵阵暖意，根据国家药品监督管理局网站消息，2026开年已经有三款创新药获批上市，其中包含2个国产创新药，分别来自恒瑞医药、百济神州；1个进口产品，来自赛诺菲。业内表示，本次普乐司兰钠注射液的获批，回应了临床在甘油三酯管理方面的迫切患者需求。开年三款创新药的密集获批，离不开国家利好政策的支持。回顾刚刚过去的2025年，我国有76个创新药获批上市，与2024年48个相比，大幅增长58.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108134829a4aaa790&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108134829a4aaa790&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1251922891.USD","LU2328871848.SGD","LU1719994722.HKD","LU1969619763.USD","BK1500","06160","BK1583","BK1588","LU0307460666.USD","LU0588546209.SGD","LU1770034418.SGD","BK1574","LU1303224171.USD","06978","BK1161"],"gpt_icon":0},{"id":"1197547631","title":"百济神州（6160）更新2025年12月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1197547631","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197547631?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:17","pubTimestamp":1767777421,"startTime":"0","endTime":"0","summary":"百济神州有限公司于2026年1月7日发布了截至2025年12月31日的股份变动月报表。根据公告，公司当月无新增发行、购回或注销，已发行股份总数相较上月底保持不变。截至2025年12月31日，公司于香港联交所上市的普通股数量为1,425,622,549股，上海证券交易所科创板上市的人民币股份数量为115,055,260股，两部分均与上月底持平。截至报告期末，公司总股本继续保持稳定。公司同时强调其所有发行和股份管理工作均符合香港联交所《上市规则》及其他相关法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"gpt_icon":0},{"id":"2601787308","title":"百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2601787308","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601787308?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:49","pubTimestamp":1767775792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年12月31日，董事会及╱或董事会薪酬委员会根据2016期权及激励计划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制股份单位相当于69.32万股股份，约占本公告之日公司发行股份总数的0.04%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688235","ONC","LU1969619763.USD","LU1719994722.HKD","BK4526","LU0307460666.USD","LU1303224171.USD","06160","BK1500","LU1770034418.SGD","BK4585","BK1588","LU1251922891.USD","BK4139","LU0588546209.SGD","BK1161","LU2328871848.SGD","BK0239","BK1583"],"gpt_icon":0},{"id":"2601981355","title":"苏州检查分局、审评核查苏州分中心助力百济神州1类新药“百悦达”加速上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601981355","media":"江苏药品监管","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601981355?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:02","pubTimestamp":1767697327,"startTime":"0","endTime":"0","summary":"作为服务企业创新发展的“护航者”，苏州检查分局、审评核查苏州分中心全程精准对接、高效服务，为这款全球领先新药的加速落地提供了坚实保障。4月28日、5月12日该药品两个适应症上市申请先后获受理后，苏州检查分局、审评核查苏州分中心迅速组建专业检查团队，提前梳理注册核查及GMP符合性检查的关键要点，与企业同步开展检查方案研讨，明确检查标准和时间节点，最大限度压缩准备周期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106190827a6fa26b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106190827a6fa26b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1251922891.USD","LU0307460666.USD","LU0588546209.SGD","BK1500","LU1303224171.USD","LU1969619763.USD","LU1770034418.SGD","BK1161","LU1719994722.HKD","06160","LU2328871848.SGD","BK1583","BK1588"],"gpt_icon":0},{"id":"1170001608","title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1170001608","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170001608?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:02","pubTimestamp":1767697320,"startTime":"0","endTime":"0","summary":"1月6日，$百济神州$宣布，其自研的1类新药新型BCL2抑制剂百悦达获得国家药品监督管理局附条件批准，用于治疗既往接受过至少包含布鲁顿酪氨酸激酶抑制剂在内的一种系统治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤成人患者，以及既往接受过至少两种系统性治疗的复发或难治性套细胞淋巴瘤成人患者。基于此次获批，索托克拉将为已接受过BTK抑制剂治疗的CLL/SLL患者带来新的治疗选择，更使其成为国内首款且唯一可用于治疗MCL的BCL2抑制剂。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","LU0307460666.USD","LU1719994722.HKD","BK0239","LU1303224171.USD","LU2328871848.SGD","688235","06160","BK4139","BK1500","BK4526","LU1770034418.SGD","BK4585","BK1161","LU0588546209.SGD","LU1251922891.USD","BK1583","LU1969619763.USD","BK1588"],"gpt_icon":0},{"id":"2601813530","title":"每日卖空追踪 | 百济神州 01月06日卖空量成交33.25万股，卖空比例为6.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601813530","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601813530?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:30","pubTimestamp":1767688236,"startTime":"0","endTime":"0","summary":"百济神州北京时间01月06日，跌1.03%，卖空量成交33.25万股，较上一交易日减少66.55%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106163640a6f98695&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106163640a6f98695&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1588","LU1719994722.HKD","LU1770034418.SGD","LU1251922891.USD","LU1969619763.USD","BK1500","LU1303224171.USD","06160","LU2328871848.SGD","LU0588546209.SGD","BK1583","LU0307460666.USD"],"gpt_icon":0},{"id":"2601135648","title":"有成熟出海能力的药企，长期增长更有保障","url":"https://stock-news.laohu8.com/highlight/detail?id=2601135648","media":"明大教主","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601135648?lang=zh_cn&edition=full","pubTime":"2026-01-06 14:51","pubTimestamp":1767682313,"startTime":"0","endTime":"0","summary":"尤其是百奥赛图，我原以为百奥A股发行后筹码压力增强，可能会带来H股情绪抛压，百奥H股怎么不得回撤一波？现我国在研创新药管线约占全球30%，位列全球第二，百奥赛图的模型动物和临床前CRO业务必然会受益，抗体开发业务间接受益。另外百奥也是最早实现模型动物“反向出海”的国内企业，海外MNC认可度最高。相比于一些只能在国内靠集采、国谈或是价格内卷占份额获益的企业，我还是更看重赚外汇能力成熟、成长性确定的百奥赛图。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106150109a6f91e9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106150109a6f91e9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","BK1161","BK1583","06160","LU1303224171.USD","LU1770034418.SGD","LU0588546209.SGD","LU1969619763.USD","BK1588","LU1251922891.USD","LU0307460666.USD","LU1719994722.HKD","BK1500","LU2328871848.SGD"],"gpt_icon":0},{"id":"2601868644","title":"中信建投：脑机接口有望打开万亿市场空间 需发掘国家政策支持和具有真实需求“真脑机”","url":"https://stock-news.laohu8.com/highlight/detail?id=2601868644","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601868644?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:27","pubTimestamp":1767670058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，脑机接口升级为十五五产业战略，多重政策强力支持下，产业落地有望提速，建议重视投资机遇。脑机接口是医疗投资也是科技投资，短期来看主要应用于疾病治疗，长期来看若能实现增强人、并与AI和机器人融合，有望打开万亿市场空间。在投资方向选择方面，非侵入式和侵入式脑机接口无优劣之分，但需发掘国家政策支持和具有真实需求的“真脑机”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2045819591.USD","LU2242644610.SGD","01099","03347","LU0708995583.HKD","02269","LU1046422090.SGD","01801","BK1161","SHPMY","BK1576","LU2125910500.SGD","02607","09926","02359","BK1583","06978","BK1141","BK1574","LU0320764599.SGD","00013","06160","LU0052750758.USD","01177"],"gpt_icon":0},{"id":"2601917854","title":"重磅，百济神州又一款1类新药迎来新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2601917854","media":"北京药研汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601917854?lang=zh_cn&edition=full","pubTime":"2026-01-06 08:01","pubTimestamp":1767657678,"startTime":"0","endTime":"0","summary":"特应性皮炎，这一慢性、复发性、炎症性皮肤病，近年来在全球范围内发病率持续上升，给患者的生活质量带来了严重影响。BGB-45035是百济神州开发的一款IRAK4 CDAC，正被研究用于治疗各类自身免疫性疾病。据报道，该药物具有潜力诱导更深、更快的IRAK4降解，并且细胞因子抑制作用更强，是百济神州在自有CDAC平台上研发的第二款靶向降解剂。IRAK4作为先天免疫关键靶点，近年来受到多家药企关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106081138a6f7b13c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106081138a6f7b13c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4585","BK4139","06160"],"gpt_icon":0},{"id":"2601854186","title":"千亿出海潮：中国创新药企驶入全球深水区","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854186?lang=zh_cn&edition=full","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01167","00013","BMS","06160","01541","BK4585","BK4139","CXO","ONC","BK4526","01801","02509"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0468},{"period":"1month","weight":0.0458},{"period":"3month","weight":0.0947},{"period":"6month","weight":0.2275},{"period":"1year","weight":0.8781},{"period":"ytd","weight":0.1344}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0243},{"period":"3month","weight":0.0459},{"period":"6month","weight":0.0853},{"period":"1year","weight":0.3957},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeOne Medicines AG（原名：BeiGene Ltd）是一家全球肿瘤学公司，致力于为全球癌症患者研发新疗法。该公司产品组合涵盖血液学和实体瘤，致力于开发多样化的新型疗法。其产品包Brukinsa、Tevimbra和Pamiparib。Brukinsa是一种口服的布鲁顿酪氨酸激酶(BTK)小分子抑制剂。Tevimbra是一种人源化免疫球蛋白G4（IgG4）抗程序性细胞死亡蛋白1（PD-1）单克隆抗体，具有高亲和力和对PD-1的结合特异性。Tevimbra旨在最大限度地减少与巨噬细胞上Fc-γ（Fcy）受体的结合，帮助人体免疫细胞检测和对抗肿瘤。该公司正在开发的产品线包括Sonrotoclax、Tarlatamab、Zanidatamab、Blinatumomab、BGB-26808、BGB-R046、BG-68501、BG-C9074、BGB-43395、Xaluritamig等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.02539},{"month":2,"riseRate":0.571429,"avgChangeRate":0.046604},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.052519},{"month":4,"riseRate":0.428571,"avgChangeRate":0.037509},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.052709},{"month":6,"riseRate":0.428571,"avgChangeRate":0.007027},{"month":7,"riseRate":0.857143,"avgChangeRate":0.097108},{"month":8,"riseRate":0.857143,"avgChangeRate":0.058603},{"month":9,"riseRate":0.5,"avgChangeRate":0.025162},{"month":10,"riseRate":0.5,"avgChangeRate":-0.027038},{"month":11,"riseRate":0.625,"avgChangeRate":0.118183},{"month":12,"riseRate":0.125,"avgChangeRate":-0.07577}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}